DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$3.31 USD
-0.14 (-4.06%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $3.39 +0.08 (2.42%) 6:54 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DMAC 3.31 -0.14(-4.06%)
Will DMAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DMAC
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
Other News for DMAC
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
Lake Street Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC)
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
Craig-Hallum Releases a Buy Rating on Diamedica Therapeutics (DMAC)
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia